Hybrid systems based on “drug – in cyclodextrin – in nanoclays” for improving oxaprozin dissolution properties

International Journal of Pharmaceutics

Volumn 509, Issue 1-2, 2016, Pages 8-15

  Mura, Paola ^a   Maestrelli, Francesca ^a   Aguzzi, Carola ^b   Viseras, César ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GRANADA   (Spain)

^c CSIC   (Spain)

Author keywords

Clay cyclodextrin hybrid systems; Cyclodextrin complexation; Nanoclays; Oxaprozin; Sepiolite

Indexed keywords

ATTAPULGITE; BENTONITE; CYCLODEXTRIN; MAGNESIUM TRISILICATE; OXAPROZIN; ALUMINUM SILICATE; ANTIINFLAMMATORY AGENT; BETA CYCLODEXTRIN DERIVATIVE; CLAY; MAGNESIUM DERIVATIVE; MAGNESIUM SILICATE; NANOPARTICLE; PROPIONIC ACID DERIVATIVE; SILICON DERIVATIVE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VITRO STUDY; NANOENCAPSULATION; POWDER FLOW; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMOGRAVIMETRY; X RAY DIFFRACTION; CHEMISTRY; SOLUBILITY;

ALUMINUM SILICATES; ANTI-INFLAMMATORY AGENTS; BENTONITE; BETA-CYCLODEXTRINS; CYCLODEXTRINS; MAGNESIUM COMPOUNDS; MAGNESIUM SILICATES; NANOPARTICLES; PROPIONATES; SILICON COMPOUNDS; SOLUBILITY;

EID: 84977656179     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.05.028     Document Type: Article

References (39)

1. Aguzzi, C., Cerezo, P., Viseras, C., Caramella, C., Use of clays as drug delivery systems: possibilities and limitations. Appl. Clay Sci. 36 (2007), 22–36.
2. Ambrogi, V., Fardella, G., Grandolini, G., Perioli, L., Intercalation compounds of hydrotalcite-like anionic clays with antiinflammatory agents—I. Intercalation and in vitro release of ibuprofen. Int. J. Pharm. 220 (2001), 23–32.
3. Ambrogi, V., Fardella, G., Grandolini, G., Nocchetti, M., Perioli, L., Effect of hydrotalcite-like compounds on the aqueous solubility of some poorly water-soluble drugs. J. Pharm. Sci. 92 (2003), 1407–1418.
4. Ann, H.J., Kim, K.M., Choi, J.S., Kim, C.K., Effects of cyclodextrin derivatives on bioavailability of ketoprofen. Drug Dev. Ind. Pharm. 23 (1997), 397–401.
5. Bragagni, M., Maestrelli, F., Mennini, N., Ghelardini, C., Mura, P., Liposomal formulations of prilocaine: effect of complexation with hydroxypropyl-β-cyclodextrin on drug anesthetic effect. J. Lipos. Res. 20 (2010), 315–322.
6. Brewster, M.E., Loftsson, T., Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59 (2007), 645–666.
7. Cavalli, R., Peira, E., Caputo, O., Gasco, M.R., Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int. J. Pharm. 182 (1999), 59–69.
8. Challa, R., Ahuja, A., Ali, J., Khar, R.K., Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6 (2005), 329–357.
9. Choy, J.H., Choi, S.J., Oh, J.M., Park, T., Clay minerals and layered double hydroxides for novel biological applications. Appl. Clay Sci. 36 (2007), 122–132.
10. Cirri, M., Bragagni, M., Mennini, N., Mura, P., Development of a new delivery system consisting in drug – In cyclodextrin – in nanostructured lipid carriers for ketoprofen topical delivery. Eur. J. Pharm. Biopharm. 80 (2012), 46–53.
11. Del Hoyo, C., Rives, V., Vicente, M.A., Adsorption of melted drugs on smectite. Clays Clay Miner. 44 (1996), 424–428.
12. Elkheshen, S.A., Ahmed, S.M., Al-Quadeib, B.T., Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin: in vitro and in vivo drug availability. Pharm. Ind. 64 (2002), 708–715.
13. Grubel, P., Bhaskar, K.R., Cave, D.R., Garik, P., Stanley, H.E., Lamont, J.T., Interaction of an aluminium–magnesium-containing antacid and gastric mucous: possible contribution to the cytoprotective function of antacids. Aliment. Pharmacol. Ther. 11 (1997), 139–145.
14. Gursoy, R.N., Benita, S., Self-emulsifying drug delivery systems for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 (2004), 173–182.
15. Hauss, D.J., Oral lipid-based formulations. Adv. Drug Deliv. Rev. 59 (2007), 667–676.
16. ® S100 based pH-responsive microspheres of zaleplon by spray-drying: tailoring the drug release properties. Powder Technol. 283 (2015), 334–343.
17. Kiss, T., Fenyvesi, F., Bacskay, I., Varadi, J., Fenyvesi, E., Ivanyi, R., Szente, L., Tosaki, A., Vecsernyes, M., Evaluation of cytotoxicity of b-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur. J. Pharm. Sci. 40 (2010), 376–380.
18. Li, D.X., Han, M.J., Balakrishnan, P., Yan, Y.D., Oh, D.H., Joe, J.H., Seo, Y., Kim, J.O., Park, S.M., Yong, C.S., Choi, H.G., Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. Arch. Pharm. Res. 33 (2010), 95–101.
19. Maestrelli, F., Cecchi, M., Cirri, M., Capasso, G., Mennini, N., Mura, P., Comparative study of oxaprozin complexation with natural and chemically modified cyclodextrins in solution and in the solid state. J. Incl. Phenom. Macrocycl. Chem. 63 (2009), 17–25.
20. Maestrelli, F., Gonzalez-Rodriguez, M.L., Rabasco, A.M., Ghelardini, C., Mura, P., New drug-in cyclodextrin-in deformable liposomes formulations to improve the therapeutic efficacy of local anaesthetics. Int. J. Pharm. 395 (2010), 222–231.
21. Marianecci, C., Rinaldi, F., Esposito, S., Di Marzio, L., Carafa, M., Niosomes encapsulating ibuprofen-cyclodextrin complexes: preparation and characterization. Curr. Drug Targets 14 (2015), 1070–1078.
22. Mennini, N., Furlanetto, S., Cirri, M., Mura, P., Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-ß-cyclodextrin-PVP complex. Eur. J. Pharm. Biopharm. 80 (2012), 67–75.
23. Mura, P., Maestrelli, F., Cecchi, M., Bragagni, M., Almeida, A., Development of a new delivery system consisting in drug-in cyclodextrin-in PLGA nanoparticles. J. Microencapsulation 27 (2010), 479–486.
24. Muraoka, A., Tokumura, T., Machida, Y., Evaluation of the bioavailability of flurbiprofen and its β-cyclodextrin inclusion complex in four different doses upon oral administration to rats. Eur. J. Pharm. Biopharm. 58 (2004), 667–671.
25. Ojijo, V., Sinha Ray, S., Processing strategies in bionanocomposites. Prog. Polym. Sci. 38 (2013), 1543–1589.
26. Otero Espinar, F.J., Anguiano Igea, S., Blanco Mendez, J., Vila Jato, J.L., Reduction in the ulcerogenicity of naproxen by complexation with ß-cyclodextrin. Int. J. Pharm. 70 (1991), 35–41.
27. Ozdemir, Y., Dogan, M., Alkan, M., Adsorption of cationic dyes from aqueous solutions by sepiolite. Micropor. Mesopor. Mat. 96 (2006), 419–427.
28. Park, J.K., Choy, Y.B., Oh, J.M., Kima, J.Y., Hwanga, S.J., Choy, J.H., Controlled release of donepezil intercalated in smectite clays. Int. J. Pharm. 359 (2008), 198–204.
29. Paulus, H.E., Actions and toxicity of non-steroidal antiinflammatory drugs. Curr. Opin. Rheumatol. 7 (1995), 159–166.
30. Perioli, L., Ambrogi, V., Nocchetti, M., Sisani, M., Pagano, C., Preformulation studies on host–guest composites for oral administration of BCS class IV drugs: hTlc and furosemide. Appl. Clay Sci. 53 (2011), 696–703.
31. Rojtanatanya, S., Pongjanyakul, T., Propranolol–magnesium aluminum silicate complex dispersions and particles: characterization and factors influencing drug release. Int. J. Pharm. 383 (2008), 106–115.
32. Rothstein, R., Safety profiles of leading non steroidal anti-inflammatory drugs. Am. J. Med. 105 (1998), 39–43.
33. Uekama, K., Hirayama, F., Tetsumi, I., Cyclodextrin drug carrier systems. Chem. Rev. 98 (1998), 2045–2076.
34. Vasconcelos, T., Sarmento, B., Costa, P., Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12 (2007), 1068–1075.
35. Vega, E., Egea, M.A., Garduño-Ramírez, M.L., García, M.L., Sánchez, E., Espina, M., Calpena, A.C., Flurbiprofen PLGA-PEG nanospheres: role of hydroxypropyl-β-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy. Colloid Surf aceB 110 (2013), 339–346.
36. Viseras, C., Cerezo, P., Sanchez, R., Salcedo, I., Aguzzi, C., Current challenges in clay minerals for drug delivery. Appl. Clay Sci. 48 (2010), 291–295.
37. Viseras, C., Aguzzi, C., Cerezo, P., Medical and health applications of natural mineral nanotubes. Pasbakhsh, G.J., (eds.) Natural Mineral Nanotubes: Properties and Applications, 2015, Apple Academic Press, Oakville, Canada and Waretown NJ, 437–448.
38. Yazdanian, M., Briggs, K., Jankovsky, C., Hawi, A., The high solubility definition of the current FDA guidance on Biopharmaceutical Classification system may be too strict for acidic drugs. Pharm. Res. 21 (2004), 293–299.
39. Zheng, J.P., Luan, L., Wang, H.Y., Xi, L.F., Yao, K.D., Study on ibuprofen/montmorillonite intercalation composites as drug release system. Appl. Clay Sci. 36 (2007), 297–301.